Table 3.
Results of uni- and multivariate analysis (Cox proportional hazard model) showing correlation of RFS with clinicopathological factors in patients with breast cancer
| Variable | Univariate | Multivariate | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| pStage (vs. Stage I) | 2.60 | 1.01–6.69 | 0.05 | 1.72 | 0.48–6.10 | 0.40 |
| pLN (vs. negative) | 2.55 | 1.08–6.01 | 0.03 | 1.65 | 0.52–5.17 | 0.39 |
| Pathological tumor size (vs. T1) | 1.27 | 0.53–3.07 | 0.59 | |||
| Grade (vs. 1–2) | 1.14 | 0.46–2.82 | 0.78 | |||
| ER (vs. positive) | 1.33 | 0.54–3.30 | 0.54 | |||
| PR (vs. positive) | 1.54 | 0.65–3.67 | 0.32 | |||
| HER2 (vs. negative) | 0.46 | 0.06–3.39 | 0.44 | |||
| Ki-67 (vs. < 10%) | 4.15 | 0.95–18.1 | 0.06 | |||
| Adjuvant chemotherapy (vs. non-therapy) | 1.47 | 0.62–3.51 | 0.38 | |||
| Adjuvant endocrinetherapy (vs. non-therapy) | 0.97 | 0.38–2.50 | 0.95 | |||
| TP53 status by signature (vs. wild-type) | 3.96 | 1.45–10.8 | 0.01 | 3.73 | 1.36–10.20 | 0.01 |
pStage pathological stage, pLN pathological lymph node, ER estrogen receptor, PgR progesterone receptor, HER2 human epidermal growth factor receptor type 2, HR hazard ratio, CI confidence interval